Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 592 followers
Latest posts
Last updated 2 days ago
Bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B
2 days ago
Nearly 1 million people in Japan live with chronic hepatitis B, a...
Linerixibat accepted for priority review in China for cholestatic pruritus in patients with primary biliary cholangitis
2 days ago
Submission based on data from positive GLISTEN phase III trial
ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing
3 days ago
VH184, the first, third‑generation integrase inhibitor in development shows potential for up...
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen
3 days ago
Results reinforce lotivibart’s ultra long-acting potential with the trial progressing to evaluate...
GSK enters agreement to acquire 35Pharma Inc.
3 days ago
Includes HS235, a potentially best-in-class activin signaling inhibitor in clinical development for...
ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM
10 days ago
Final data from LATITUDE study show switch to long-acting injectable treatment reduced...
GSK’s Arexvy associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows
11 days ago
Reduction observed in RSV-related hospitalisations in adults aged ≥60 years
ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026
11 days ago
First-in-human data for long-acting formulations of VH184 and early data for capsid...
Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps
11 days ago
Exdensur is the first and only ultra-long-acting biologic in the EU to...
GSK’s RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older
18 days ago
RSV affects over six million people aged 60 and older in China...
Nucala (mepolizumab) approved by the European Commission for the treatment of chronic obstructive pulmonary disease (COPD)
22 days ago
Approval based on results from MATINEE showing significant reduction in the rate...
GSK delivers strong 2025 performance and re-affirms long-term outlooks
25 days ago
Full year and Q4 2025 highlights